Over the past few years the management of patients with metastatic renal cell carcinoma has changed substantially. Although the development of targeted therapies has improved the prognosis of many patients with renal cell carcinoma, a large subset of patients who might benefit from targeted therapies do not receive such treatments.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Smaldone, M. C. et al. Temporal trends and factors associated with receipt of systemic therapy among patients undergoing cytoreductive nephrectomy: an analysis of the national cancer database. J. Urol. http://dx.doi.org/10.1016/j.juro.2014.10.095.
Mickish, J. G. H. et al. Radical nephrectomy plus interferon-α-based immunotherapy compared with interferon α alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358, 966–970 (2001).
Flanigan R. C. et al. Cytoreduction nephrectomy in metastatic renal cancer: the results of Southwest Oncology Group trial 8949. Proc. Am. Soc. Clin. Oncol. 19, 2a (2000).
Tsao, C. K. et al. Trends in the use of cytoreductive nephrectomy in the United States. Clin. Genitourin. Cancer 10, 159–163 (2012).
Choueiri, T. K. et al. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J. Urol. 185, 60–66 (2011).
US National Library of Medicine. ClinicalTrials.gov [online], (2014).
US National Library of Medicine. ClinicalTrials.gov [online], (2012).
Small, A. C. et al. Prevalence and characteristics of patients with metastatic cancer who receive no anticancer therapy. Cancer 118, 5947–5954 (2012).
Hudes, G. et al. Temsirolimus, interferon α, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356, 2271–2281 (2007).
Heng, D. Y. C. et al. Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. Ann. Oncol. 25, 149–154 (2014).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Mehrazin, R., Galsky, M. Systemic therapy—differentiating the achievable from the achieved. Nat Rev Urol 12, 128–129 (2015). https://doi.org/10.1038/nrurol.2014.358
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2014.358
